Myoview (Tetrofosmin)

Tetrofosmin, labeled with technetium‑99m, is a lipophilic cation that readily crosses cell membranes and accumulates in the mitochondria of viable myocardial cells in proportion to regional blood flow. After intravenous injection, the gamma emissions from technetium‑99m are captured by a gamma camera, producing perfusion images.

The prescribed dose of Myoview is determined by the ordering physician based on the imaging protocol, the patient’s weight, and the activity of technetium‑99m used for reconstitution. The product is supplied as a kit containing 0.5 mg tetrofosmin to be mixed with the appropriate amount of technetium‑99m.

The safety of Myoview in pregnant or nursing women has not been established. It should be used only if the diagnostic benefit outweighs any potential risk to the fetus or infant, and appropriate radiation protection measures should be applied.

To place an order, submit an enquiry on the Myoview product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Myoview (technetium‑99m tetrofosmin) offers rapid myocardial uptake and fast clearance, providing high‑quality SPECT images with lower radiation dose compared with thallium‑201 agents. Compared with technetium‑99m sestamibi, tetrofosmin has similar imaging characteristics but may allow slightly shorter imaging times due to its faster hepatic clearance.

Myoview kits should be stored at 2‑8 °C, protected from light, and kept in the original packaging to maintain stability. Do not freeze or shake the vial. Once reconstituted with technetium‑99m, the solution should be used promptly according to the manufacturer’s instructions.

Myoview is administered intravenously as a single injection. The kit is reconstituted with technetium‑99m per the supplied instructions, and the resulting solution is injected into a peripheral vein. Imaging is performed at a defined interval after injection, depending on the stress or rest protocol selected by the nuclear cardiology team.

The most serious risks include rare allergic reactions such as anaphylaxis, significant hypotension, and cardiac arrhythmias. Because the product contains a radioactive isotope, radiation exposure to the patient and staff must be managed according to regulatory guidelines and institutional radiation safety protocols.

Myoview should be avoided in patients with known hypersensitivity to tetrofosmin, technetium‑99m compounds, or any component of the kit. It is also contraindicated in pregnant women unless the diagnostic benefit justifies the potential risk, and caution is advised in breastfeeding mothers and patients with severe uncontrolled cardiac conditions.